The Effect of Low Molecular Weight Heparins on Placentation: A Rat Model Study

Gülizar Özer; Çağlar Yıldız; Hatice Özer; Ali Çetin

doi:10.17776/csj.1169083

EN

The Effect of Low Molecular Weight Heparins on Placentation: A Rat Model Study

Abstract

Low molecular weight heparins (LMWHs) have been used for the treatment for recurrent pregnancy loss (RPL) for a long time. We aimed to investigate the efficacy of the LMWHs on angiogenesis and apoptosis during placentation. A total of twenty-four rats were randomly divided into three groups each containing 8 rats: normal saline; enoxaparine sodium 0.4 ml, and enoxaparine sodium 0.8 ml were given to the Group 1, 2 and 3, respectively. Normal saline and enoxaparine sodium 0.4 ml or 0.8 ml were given to the rats beginning on the day the pregnancy was detected and continued until the 15th day of the pregnancy. The tissues containing placental decidual zone were immunostained for vascular endothelial growth factor A (VEGF-A) and caspase 7. The decidual and placental VEGF-A and the decidual caspase 7 immunostaining scores of all of the groups were high, however, there were no statistically significant differences among the groups (p>0.05). On the other hand, the placental caspase 7 immunostaining scores of the normal saline group were significantly lower than those of the enoxaparine sodium 0.4 and the enoxaparine sodium 0.8 groups (p<0.05). LMWHs seem to have effects on placental angiogenesis and apoptosis.

Keywords

References

[1] Bick R.L., Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group, Clin. Appl. Thromb. Hemost., 6 (3) (2000) 115-125.
[2] Ford H. B., Schust D. J., Recurrent pregnancy loss: etiology, diagnosis, and therapy, Rev. Obstet. Gynecol., 2 (2) (2009) 76-83.
[3] Greer I.A., Inherited thrombophilia and venous thromboembolism. Best Pract. Res. Clin. Obstet. Gynaecol., 17 (3) (2003) 413-425.
[4] Robertson L., Wu O., Langhorne P., Twaddle S., Clark P., Lowe G.D.O., Walker I.D., Greaves M., Brenkel I., Regan L., Greer I. A., for TheThrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study, Thrombophilia in pregnancy: a systematic review, Br. J. Haematol., 132 (2) (2006) 171-196.
[5] Blumenfeld Z., Brenner B., Thrombophilia-associated pregnancy wastage, Fertil. Steril., 72 (5) (1999) 765-774.
[6] Ingman K., Cookson V.J.K.W., Jones C.J.P., Aplin J.D., Characterisation of hofbauer cells in first and second trimester placenta: incidence, phenotype, survival in vitro and motility, Placenta, 31 (6) (2010) 535-544.
[7] Poole, T.J., Coffin, J. D., Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern, J. Exp. Zool., 251 (2) (1989) 224-231.
[8] Speroff L., Fritz M.A., In: Taylor, H.S. (Ed). Klinik Jinekolojik Endokrinoloji ve İnfertilite. 7th ed. İstanbul: Güneş Kitabevi (2007).

[9] Toder V., Carp H., Fein A. Torchinsky A., The role of pro- and antiapoptotic molecular interactions in embryonic maldevelopment, Am J Reprod Immunol., 48 (4) (2002) 235-244.
[10] Pierangeli S.S., Pojen P.C., Raschi E., Scurati S., Grossi C., Borghi M.O., Palomo I., Harris E.N., Meroni P.L., Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms, Semin. Thromb. Hemost,, 34 (3) (2008) 236-250.
[11] Berker B., Cengiz L., Gestasyonel Trombofili, Maternal Fetal Tıp & Perinatoloji, (13) (2001) 725-729.
[12] Brenner B., Hoffman R., Blumenfeld Z., Weiner Z., Younis J.S., Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin, Thromb. Haemost., 83 (05) (2000) 693-697.
[13] Price G.C., Thompson S.A, Kam P.C.A., Tissue factor and tissue factor pathway inhibitor, Anaesthesia, 59 (5) (2004) 483-492.
[14] Mätzsch T., Bergqvist D., Hedne U., Ostergaard P., Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers, Thromb. Haemost., 57 (01) (1987) 97-101.
[15] Watson E.D., Cross J.C., Development of structures and transport functions in the mouse placenta, Physiology, 20 (3) (2005) 180-193.
[16] Brosens I., Pijnenborg, R., Vercruysse L., Romero R., The “Great Obstetrical Syndromes” are associated with disorders of deep placentation, Am. J. Obstet. Gynecol., 204 (2011) 193–201.
[17] Creeth H.D.J., John R.M., The placental programming hypothesis: placental endocrine insufficiency and the co-occurrence of low birth weight and maternal mood disorders, Placenta, 98 (2020) 52–59.
[18] Davies J.E., Pollheimer J., Yong H.E.J., et al., Epithelial-mesenchymal transition during extravillous trophoblast differentiation, Cell Adh. Migr., 10 (3) (2016) 310-321.
[19] İrtegün S., Ağaçayak E., Deveci E., Preeklamptik ve normotansif plasentalarda VEGF ve Vimentin ekspresyon düzeylerinin immunohistokimya ve Western Blot yöntemleri ile incelenmesi, Dicle Tıp Derg., 43 (3) (2016) 400-405.
[20] Flint E.J., Cerdeira A.S., Redman C.W., Vatish M., The role of angiogenic factors in the management of preeclampsia, Acta Obstet Gynecol Scand , 98 (6) (2019) 700-707.
[21] Lunghi L., Ferretti M. E., Medici S., Biondi C., Vesce F., Control of human trophoblast function, Reprod. Biol. Endocrinol., 5 (6) (2007) 1-14.
[22] Deruelle P., Coulon C., The use of low molecular weight heparins in pregnancy, how safe are they? Curr. Opin. Obstet. Gynecol., 19 (6) (2007) 573-577.
[23] De Carolis S., Ferrazzani S., De Stefano V., Garofalo S., Fatigante G., Rossi E., Leone G., Caruso A., Inherited thrombophilia: treatment during pregnancy, Fetal. Diagn. Ther., (21) (2006) 281-286.
[24] Di Simone N., Di Nicuolo F., Sanguinetti M., Ferrazzani S., D'Alessio M. C., Castellani R., Bompiani A., Caruso A., Low-molecular weight heparin induces in vitro trophoblast invasiveness: role of matrix metalloproteinases and tissue inhibitors, Placenta, 28 (4) (2007) 298-304.
[25] Monien S., Kadecki O., Baumgarten S., Salama A., Dörner T., Kiesewetter H., Use of heparin in women with early and late miscarriages with and without thrombophilia, Clin. Appl. Thromb. Hemost., 15 (6) (2009) 636-644.
[26] Sarto A., Rocha M., Geller M., Capmany C., Martinez M., Quintans C., Donaldson M., Pasqualini R. S., Treatment with enoxaparin adapted to the fertility programs in women with recurrent abortion and thrombophilia, Medicina, 61 (4) (2001) 406-412.
[27] Sobel M.L., Kingdom J., Drewlo S., Angiogenic response of placental villi to heparin, Obstet. Gynecol., 117 (6) (2011) 1375-1383.
[28] Xia H.F., Sun J., Sun Q. H., Yang Y., Peng J.P., Implantation-associated gene-1 (Iag-1): a novel gene involved in the early process of embryonic implantation in rat, Hum. Reprod., 23 (7) (2008) 1581-1593.
[29] Perez M.J., Macias R.I.R., Marin J.J.G., Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid, Placenta, 27 (1) (2006) 34-41.
[30] Yuan Z., Mei Z., Fengyan Liu., Low molecular weight heparin inhibits cell apoptosis in the placenta of rats with preeclampsia-like symptoms. Nan Fang Yi Ke Da Xue Xue Bao, 32 (6) (2012) 862-6.
[31] Fox H., Wells M., Haines and Taylor, Obstetrical and Gynaecological Pathology.4 th ed. Churchill Livingstone; (1995).
[32] Battistelli M., Burattini S., Pomini F., Scavo M., Caruso A., Falcieri E., Ultrastructural study on human placenta from intrauterin growth retardation cases, Micros. Res. Tech., 65 (2004) 150-158.
[33] Altshuler G., A conceptual approach to placental pathology and pregnancyoutcome, Semin. Diagn. Pathol., 10(3) (1993) 204-221.

Details

Primary Language

English

Subjects

Structural Biology

Journal Section

Research Article

Authors

Gülizar Özer ^*
0000-0002-3107-2475
Türkiye

Çağlar Yıldız
0000-0003-3150-3340
Türkiye

Hatice Özer
0000-0001-6479-3626
Türkiye

Ali Çetin
0000-0002-8621-7221
Türkiye

Publication Date

December 27, 2022

Submission Date

August 31, 2022

Acceptance Date

November 27, 2022

Published in Issue

Year 2022 Volume: 43 Number: 4

DOI

https://doi.org/10.17776/csj.1169083

IZ

https://izlik.org/JA25DN78FE

Cite

RIS / Bibtex

APA

Özer, G., Yıldız, Ç., Özer, H., & Çetin, A. (2022). The Effect of Low Molecular Weight Heparins on Placentation: A Rat Model Study. Cumhuriyet Science Journal, 43(4), 564-568. https://doi.org/10.17776/csj.1169083

Cited By

Serum estradiol (E2), progesterone (P), and human chorionic gonadotropin (HCG), D-dimer (D-D) fibrinogen (FIB) levels after low molecular weight heparin sodium on preventing miscarriage in patients with adverse pregnancy and delivery

Journal of Medical Biochemistry

https://doi.org/10.5937/jomb0-56635

Öz

Anahtar Kelimeler

The Effect of Low Molecular Weight Heparins on Placentation: A Rat Model Study

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite

Cited By

Serum estradiol (E2), progesterone (P), and human chorionic gonadotropin (HCG), D-dimer (D-D) fibrinogen (FIB) levels after low molecular weight heparin sodium on preventing miscarriage in patients with adverse pregnancy and delivery